Effect of vitamin D supplementation on diabetes type 2

Effect of vitamin D supplementation on insulin resistance and glycemic control in patients with diabetes type 2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012061110002N1

Enrollment

120

Registered

2013-03-25

Start date

2013-03-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes type 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: placebo group will recieve placebo capsul made of hard jellatinous material as the same method as intervention group. Intervention 2: Intervention group will recieve 50000 IU vitamin D

Treatment - Drugs

placebo group will recieve placebo capsul made of hard jellatinous material as the same method as intervention group.

Intervention group will recieve 50000 IU vitamin D3 every 2 weeks for 3 months orally.

Eligibility

Sex/Gender

All

Age

21 Years to 60 Years

Inclusion criteria

Inclusion criteria: inclusion critera : 1) patients with diabetes type 2 according to ADA criteria 2011 and under treatment with oral hypoglycemic agents, 2) HbA1C = 8.5%, 3) patients with 21-60 of age, 4) BMI>20 exclusion criteria : 1) end stage diseases of organs such as ESRD,chronic liver disease 2)GFR=30ml/min, 3) hypercalcemia and kidney stones,4) known primary hyperparathyroidism,5) heart diseases included ischemic heart disease, heart failure,cardiomyopathy,6) sarcoidosis,7) TB ,8) cancer,9) history of IBD ,10) pregnancy,11) SBP/SDP=175/104 mmHg ,12) consumption of vitamin D supplement over 400 IU within 2 months prior to intervention

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Insulin resistance and glycemic control (glucoseinsulin/405). Timepoint: just before and after 3 months of intervention. Method of measurement: alisun 3000 measure system.;HOMA-Beta. Timepoint: just before after 3 months of intervention. Method of measurement: glucose insulin /405.;Hb A1C. Timepoint: just before after 3 months of intervention. Method of measurement: high performance liquid chromatography method using G8 TOSO Ssystem.;HOMA - IR. Timepoint: just before and 3 months after intervension. Method of measurement: insulin* 360 / glucose -63 %.	—

Measure

Time frame

Insulin resistance and glycemic control (glucose*insulin/405). Timepoint: just before and after 3 months of intervention. Method of measurement: alisun 3000 measure system.;HOMA-Beta. Timepoint: just before after 3 months of intervention. Method of measurement: glucose* insulin /405.;Hb A1C. Timepoint: just before after 3 months of intervention. Method of measurement: high performance liquid chromatography method using G8 TOSO Ssystem.;HOMA - IR. Timepoint: just before and 3 months after intervension. Method of measurement: insulin* 360 / glucose -63 %.

—

Secondary

Measure	Time frame
Determination and comparison of the distribution of vitamin D (25 (OH) D) levels before and after treatment in both intervention and control groups. Timepoint: just before and after 3 months of intervention. Method of measurement: Chemiluminescence method using liusun system.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Homeyra Rashidi

Diabetes Research Center

hrashidi2002@yahoo.com+98 61 1336 9539

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026